The efficacy of a tart cherry drink for the treatment of patellofemoral pain in recreationally active individuals: a placebo randomized control trial

Abstract

Purpose: This study aimed to explore the efficacy of U.S. Montmorency tart cherry in treating recreationally active individuals with patellofemoral pain. Methods: Twenty-four recreationally active participants with patellofemoral pain were randomly separated into either placebo (males N = 8, females N = 4, age = 43.30 ± 7.86 yrs, mass = 72.10 ± 17.89 kg, stature = 171.16 ± 10.17, BMI = 24.31 ± 3.75 kg/m2, symptom duration = 30.18 ± 10.90) or Montmorency tart cherry (males N = 9, females N = 3, age = 41.75 ± 7.52 yrs, mass = 76.96 ± 16.64 kg, stature = 173.05 ± 7.63, BMI = 25.53 ± 4.03 kg/m2, symptom duration = 29.73 ± 11.88) groups. Both groups ingested 60 mL of either Montmorency tart cherry concentrate or taste matched placebo daily for 6 weeks. Measures of self-reported pain (KOOS-PF), psychological wellbeing (COOP WONCA), and sleep quality (PSQI) alongside blood biomarkers (C-reactive protein, uric acid, TNF alpha, creatinine, and total antioxidant capacity) and knee biomechanics were quantified at baseline and 6 weeks. Differences between groups were examined using linear mixed-effects models. Results: There was 1 withdrawal in the cherry and 0 in the placebo group and no adverse events were noted in either condition. The placebo condition exhibited significant improvements (baseline = 67.90 ± 16.18 & 6 weeks = 78.04 ± 14.83) in KOOS-PF scores compared to the tart cherry group (baseline = 67.28 ± 12.55& 6 weeks = 67.55 ± 20.61). No other statistically significant observations were observed. Conclusion: Tart cherry supplementation as specifically ingested in the current investigation does not appear to be effective in mediating improvements in patellofemoral pain symptoms in recreationally active individuals.